share_log

BioVie | 8-K: Current report

BioVie | 8-K: Current report

BioVie | 8-K：重大事件
美股SEC公告 ·  2024/09/26 05:05

Moomoo AI 已提取核心信息

BioVie has completed its previously announced best efforts public offering, raising approximately $3 million in gross proceeds. The offering included 1,360,800 shares of common stock, pre-funded warrants to purchase 600,000 shares, and warrants to purchase up to 1,960,800 shares at a combined price of $1.53 per share or pre-funded warrant. The common warrants are immediately exercisable for five years at $1.53 per share.Following the offering's completion, the company adjusted the exercise price of Acuitas Group Holdings' warrant from $10.00 to $1.53, effective September 25, 2024, in accordance with the warrant's terms. The net proceeds, after deducting approximately $210,000 in placement agent fees and offering expenses, will be used primarily for working capital and general corporate purposes.ThinkEquity served as the sole placement agent for the offering, which was conducted under the company's shelf registration statement. The securities were offered through a prospectus supplement and accompanying prospectus filed with the SEC.
BioVie has completed its previously announced best efforts public offering, raising approximately $3 million in gross proceeds. The offering included 1,360,800 shares of common stock, pre-funded warrants to purchase 600,000 shares, and warrants to purchase up to 1,960,800 shares at a combined price of $1.53 per share or pre-funded warrant. The common warrants are immediately exercisable for five years at $1.53 per share.Following the offering's completion, the company adjusted the exercise price of Acuitas Group Holdings' warrant from $10.00 to $1.53, effective September 25, 2024, in accordance with the warrant's terms. The net proceeds, after deducting approximately $210,000 in placement agent fees and offering expenses, will be used primarily for working capital and general corporate purposes.ThinkEquity served as the sole placement agent for the offering, which was conducted under the company's shelf registration statement. The securities were offered through a prospectus supplement and accompanying prospectus filed with the SEC.
BioVie已完成之前宣布的最佳努力公开发行，筹集了约300万的毛收入。此次发行包括1,360,800股普通股、可购买600,000股的预先筹资认股权证，以及最多可购买1,960,800股的认股权证，合并价格为每股1.53美元或预先筹资认股权证。这些普通认股权证在五年内可立即按每股1.53美元行权。在发行完成后，公司根据认股权证的条款，将Acuitas Group Holdings的认股权证的行权价格从10.00美元调整至1.53美元，生效日期为2024年9月25日。扣除约210,000美元的承销佣金和发行费用后的净收入，将主要用于营运资金和一般公司用途。ThinkEquity作为此次发行的唯一承销代理，发行是在公司的货架注册声明下进行的。这些证券通过附带的招股说明书及向SEC提交的招股说明书补充进行发行。
BioVie已完成之前宣布的最佳努力公开发行，筹集了约300万的毛收入。此次发行包括1,360,800股普通股、可购买600,000股的预先筹资认股权证，以及最多可购买1,960,800股的认股权证，合并价格为每股1.53美元或预先筹资认股权证。这些普通认股权证在五年内可立即按每股1.53美元行权。在发行完成后，公司根据认股权证的条款，将Acuitas Group Holdings的认股权证的行权价格从10.00美元调整至1.53美元，生效日期为2024年9月25日。扣除约210,000美元的承销佣金和发行费用后的净收入，将主要用于营运资金和一般公司用途。ThinkEquity作为此次发行的唯一承销代理，发行是在公司的货架注册声明下进行的。这些证券通过附带的招股说明书及向SEC提交的招股说明书补充进行发行。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    TuHURA Biosciences
    HURA
    -- 3.850
    Aditxt
    ADTX
    -- 10.0300
    COSCIENS Biopharma
    CSCI
    -- 4.350
    Forte Biosciences
    FBRX
    -- 7.020
    Lyell Immunopharma
    LYEL
    -- 0.582
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日